Further strengthening of leadership team following the appointment of industry stalwart Barbara Angehrn Pavik as Chief Executive Officer Accelerating advancement of novel treatments to halt disease progression in neurodegenerative diseases LAUSANNE, Switzerland and SAN FRANCISCO, Dec. 18,…
This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.